Everolimus: In advanced renal cell carcinoma

Drugs

Volumn 69, Issue 15, 2009, Pages 2115-2124

  Garnock Jones, Karly P ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; PLACEBO; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB;

ARTICLE; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLACEBOS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SIROLIMUS; TREATMENT OUTCOME;

EID: 74049090090     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203770-000000000-00000     Document Type: Article

References (31)

1. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 2009 Mar; 103 (5): 572-7
2. Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008 Nov; 35 (4): 687-701
3. Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol 2009 May; 20 Suppl. 1: i13-7
4. Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J 2008 Sep/Oct; 14 (5): 325-9
5. Escudier B, Thompson JA. Mechanism of action of everolimus in renal cell carcinoma. Med Oncol 2009; 26 Suppl. 1: S32-9
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.2.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/kidney.pdf [Accessed 2009 Jul 27]
7. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66 (4): 547-70
8. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64 (8): 861-72
9. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007 Jun 1; 13 (11): 3109-14
10. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004 Jan 1; 64 (1): 252-61
11. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997 Jul 15; 64 (1): 36-42
12. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002 Jun 15; 16 (12): 1472-87
13. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004 Jan; 24 (1): 200-16
14. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005 Aug 18; 24 (35): 5414-22
15. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009 Mar 1; 15 (5): 1612-22
16. Novartis Pharmaceuticals Corporation. Afinitor (everolimus tablets): US prescribing information [online]. Available from URL: http://www.pharma.us. novartis.com/product/pi/pdf/afinitor.pdf [Accessed 2009 Jun 24]
17. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008 Apr 1; 26 (10): 1588-95
18. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamyci pathway with everolimus: a phase I tumour pharmacody-namic study in patients with advanced solid tumours. J Clin Oncol 2008; 26 (10): 1603-10
19. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008 Apr 1; 26 (10): 1596-602
20. US FDA. Center for Drug Evaluation and Research clinical pharmacology and biopharmaceutics review for everolimus [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022334s000-ClinPharmR. pdf [Accessed 2009 Jul 27]
21. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006 Feb 1; 66 (3): 1500-8
22. Rosenberg JE, Weinberg VK, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract no. 5109]. J Clin Oncol 2008 May; 26 (15 Suppl., Part I of II): 276S
23. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002 Feb; 22 (2): 154-9
24. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 Aug 9; 372 (9637): 449-56
25. Kay A, Motzer R, Figlin R, et al. Updated data from a phase III randomized trial of Everolimus versus PBO in metastatic renal cell carcinoma [abstract no. 278]. 2009 Genitourinary Cancers Symposium; 2009 Feb 26-28; Orlando (FL) [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=64&abstractID=20488 [Accessed 2009 Jun 06]
26. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009 Jun 1; 115 (11): 2438-46
27. Jac J, Amato RJ, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy [abstract no. 5113]. J Clin Oncol 2008; 26 (15 Suppl. Pt 1): s277.
28. Plus poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago (IL)
29. Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma [abstract no. 5010]. J Clin Oncol 2008 May; 26 (15 Suppl., part I of II): 252s
30. Chan JS, Vuky J, Besaw LA, et al. A phase II study of mammalian target of rapamycin inhibitor RAD001 plus imatinib mesylate in patients with previously treated advanced renal carcinoma [abstract no. 15600]. J Clin Oncol; 25 (18 Suppl., Part I of II) [online]. Available from URL: http://meeting.ascopubs.org/ cgi/content/abstract/25/18-suppl/15600 [Accessed 2009 Jun 04]
31. Novartis Pharmaceuticals Corporation. Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy [online media release]. 2009 Aug 6. Available from URL: http://www.novartis.com/newsroom/media-releases/en/2009/1332932.shtml [Accessed 2009 Sep 18]